Jun 16, 2022 / 01:30PM GMT
Jason Butler - JMP Group LLC - Analyst
We're going to go ahead and get started here. Thank you again for joining us this morning at the JMP Securities Life Science Conference. Excited to have MorphoSys and CEO Jean-Paul Kress. Jean-Paul, great to see you in person.
Jean-Paul Kress - MorphoSys AG - CEO
Thank you.
Questions and Answers:
Jason Butler - JMP Group LLC - AnalystThere have been -- another exciting year for MorphoSys where you're continuing to execute on the launch of Monjuvi. You also have a late-stage pipeline, and some really exciting news in the last couple of days. So, maybe we start off with the most recent news, and that's -- you've out-licensed a couple of earlier-stage programs to HIBio. Can you just walk us through, I guess, the overall -- the transaction, but also your rationale for bringing on a partner for these programs?
Jean-Paul Kress - MorphoSys AG - CEO
Well, thank you, Jason, and good to see you in person.